

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandra, Virginia 22313-1450
www.usplo.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/690,044	10/16/2000	Per Lennart Lindberg	1103326-0072	3566
7470 7	590		EXAM	INER
WHITE & CASE LLP			FAN, JANE T	
PATENT DEPARTMENT 1155 AVENUE OF THE AMERICAS			ART UNIT	PAPER NUMBER
NEW YORK, NY 10036			1625	

DATE MAILED: 01/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

SUPPLEMENTAL Notice of Allowability

Application No. 09/690,044

Applicant(s)

Lindberg et al.

Examiner

Celia Chang

Art Unit 1625



The MAILING DATE of this communication appears on the c	cover sheet with the correspondence address
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAI (or previously mailed), a Notice of Allowance (PTOL-85) or other appropria THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. the initiative of the Office or upon petition by the applicant. See 37 CFR	ate communication will be mailed in due course. This application is subject to withdrawal from issue at
1. This communication is responsive to <u>notice of allowance 10/10</u>	0/03
2. X The allowed claim(s) is/are 1 and 35 (re-numbered as 1 and 2)	
3. The drawings filed on are accepted by t	he Examiner.
4. Acknowledgement is made of a claim for foreign priority under	35 U.S.C. § 119(a)-(d).
a) ☐ All b) ☐ Some* c) ☐ None of the:	
1. Certified copies of the priority documents have been rec	eived.
2. Certified copies of the priority documents have been received.	eived in Application No
3. Copies of the certified copies of the priority documents happlication from the International Bureau (PCT Rule 1	7.2(a)).
*Certified copies not received:	•
5. Acknowledgement is made of a claim for domestic priority und	ler 35 U.S.C. § 119(e) (to a provisional application).
(a) \square The translation of the foreign language provisional application	on has been received.
6. Acknowledgement is made of a claim for domestic priority und	ler 35 U.S.C. §§ 120 and/or 121.
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commoted below. Failure to timely comply will result in ABANDONMENT of the EXTENDABLE.	nunication to file a reply complying with the requirements is application. THIS THREE-MONTH PERIOD IS NOT
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s)	
8. CORRECTED DRAWINGS must be submitted.	
(a) \square including changes required by the Notice of Draftsperson's	Patent Drawing Review (PTO-948) attached
1) \square hereto or 2) \square to Paper No	
(b) \square including changes required by the proposed drawing correct approved by the examiner.	tion filed, which has been
(c) \square including changes required by the attached Examiner's American Paper No	endment/Comment or in the Office action of
Identifying indicia such as the application number (see 37 CFR 1.84(c)) shoul each sheet. The drawings should be filed as a separate paper with a transmi	
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLO attached Examiner's comment regarding REQUIREMENT FOR TI	
Attachment(s)	
1 X Notice of References Cited (PTO-892)	2 Notice of Informal Patent Application (PTO-152)
3 Notice of Draftsperson's Patent Drawing Review (PTO-948)	4 Interview Summary (PTO-413), Paper No
5 Information Disclosure Statement(s) (PTO-1449), Paper No(s).	6 Examiner's Amendment/Comment
7 Lexaminer's Comment Regarding Requirement for Deposit of Biological Material	8 🔀 Examiner's Statement of Reasons for Allowance
9 Other	

Art Unit: 1625

DETAILED ACTION

1. Claims 1 and 35 (re-numbered as 1-2) have been allowed.

2. Reason for Allowance

The following is an examiner's statement of reasons for allowance:

The instant claims are drawn to the Magnesium salt of *exclusively* the (-)-isomer of omeprazole. This exclusive salt of the stereoisomer (see RN 202742-30-1) is distinct from the prior art di-omeprazole magnesium salt (see RN 95382-33-5) disclosed in US 4,738,974 or US 5,900,424 (see CA102 and 122). In view of the highly stable complex between magnesium and omeprazole, it is unobvious to obtain the single non-complexed salt of the instant claims being made from a single isolated isomer. Claims 1 and 35 as renumbered claims 1-2 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 703-308-4702. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman, can be reached on (703) 308-4698. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

WP/Chang *Dec. 16, 2003*

Primary Examiner
Art Unit 1625